Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke
© Wagner et al.; licensee BioMed Central Ltd. 2012
Received: 28 July 2012
Accepted: 21 August 2012
Published: 24 August 2012
Bone marrow-derived mononuclear cells (BM MNC) have been effectively used to treat experimental stroke. Most of the preclinical trials have been performed in young and healthy laboratory animals, even though age and hypertension are major risk factors for stroke. To determine the influence of age on the properties of BM MNCs after cerebral ischemia, we compared the efficacy of aged and young BM MNC in an in vitro model of cerebral hypoxia and in an adapted in vivo model of stroke. Human BM MNCs were obtained from healthy young or aged donors and either co-cultured with rat hippocampal slices exposed to oxygen glucose deprivation (OGD), or transplanted intravenously 24 h after permanent middle cerebral artery occlusion in aged (18 months) spontaneously hypertensive rats (SHR). Efficacy was examined by quantification of hippocampal cell death, or respectively, by neurofunctional tests and MR investigations. Co-cultivation with young, but not with aged BM MNCs significantly reduced the hippocampal cell death after OGD. Transplantation of both young and old BM MNCs did not reduce functional deficits or ischemic lesion volume after stroke in aged SHR. These results suggest a significant impact of age on the therapeutic efficacy of BM MNCs after cerebral ischemia.
KeywordsBrain ischemia Cell transplantation Bone marrow cell transplantation Age Comorbidity SHR
Cerebral ischemia is one of the leading causes for mortality and disability in industrialized countries, and its treatment is seriously restricted by a tight therapeutic time frame. Less than 5% of stroke patients receive thrombolysis, primarily due to delayed clinical presentation . Consequently, one of the main goals of modern stroke research is an extension of the therapeutic time window. Cell based therapies might fulfil this expectation, since cells are suspected to modulate protective and restorative effects even days after the onset of brain ischemia . Bone marrow derived mononuclear cells (BM MNC) are promising candidates for acute stroke treatment, since these cells can be harvested and re-transplanted acutely in an autologous fashion . An open-label prospective study just recently showed that bone marrow harvest and reinfusion of autologous MNCs in patients with acute middle cerebral artery ischemic stroke is safe and feasible .
BM MNC transplantation in experimental models of brain ischemia and spinal cord injury resulted in a significantly improved functional recovery [5–7], and the therapeutic time window for these effects seems to be between 3 h-72 h after stroke onset . However, most of the preclinical trials have been performed in young or middle-aged, healthy laboratory animals - even though age and hypertension are crucial risk factors for stroke , and the susceptibility of the ischemic brain for cell-based therapies might be altered with age. Beyond that, age and comorbidities have to be particularly considered if autologous approaches are intended, since not only the receiving tissue but also the donor tissue (i.e. the bone marrow) is subjected to aging processes and might be altered in its functionality. In the present study we aimed to analyze the effect of age on the efficacy of BM MNC transplantation for cerebral ischemia. For this, we investigated the therapeutic efficacy of human BM MNCs obtained from aged or young donors in an ex vivo model of hypoxia-ischemia and in an in vivo model of stroke using aged hypertensive rats.
BM MNC preparation
Cryopreserved human bone marrow derived mononuclear cells (BM MNC) from young donors (n = 4; 24 ± 4 years) were obtained from Lonza (Walkersville, USA). BM MNCs have been isolated by Ficoll-Paque density gradient centrifugation according to the manufacturer’s instructions. Aged bone marrow was collected from healthy elderlies (n = 4; 68 ± 1 years) after informed consent and approval by the ethics review board of the University of Rostock, Germany. Bone marrow cells were layered above Lymphocyte Separation Medium LSM 1077 (PAA Laboratories, Coelbe, Germany) and centrifuged at 800 × g for 20 min. The mononuclear cell layer was removed and washed one time with PBS (400 × g, 10 min). Finally, BM MNCs were resuspended in 10% dimethyl sulfoxide (DMSO; Merck, Hohenbrunn, Germany) and stored in liquid nitrogen. Prior to use, BM MNCs from both sources were thawed rapidly and separated by 75 U/mL Accutase treatment and washed in RPMI (PAA Laboratories, Pasching, Austria).
Determination of hematopoietic stem cells
The hematopoietic potential of BM MNCs was determined using a methylcellulose based colony forming unit assay. 1.1x10E5/mL cells were mixed with methylcellulose, plated on petri dishes and incubated for 14 days at 37°C in 5% CO2 and 95% humidity. The colonies were divided into burst forming units – erythroid (BFU-E) and granulocyte/monocyte colony forming units (CFU-GM) and subsequently counted. The amount and vitality of CD34+ cells were quantified by FACSCalibur flow cytometer (Becton Dickinson) using 7-Amino-actinomycin D (7AAD, BD Biosciences), an APC-coupled anti-CD34 and a PC7-coupled anti-CD45 antibody (Beckman Coulter, Krefeld, Germany).
Organotypic hippocampal slice cultures and oxygen-glucose deprivation
Organotypic hippocampal slice cultures (OHC) were prepared from postnatal Wistar rats (day 8-9, Harlan-Winkelman, Borchen, Germany) as described previously . Animals were sacrificed by decapitation. Hippocampi were dissected and transversally sliced (350 μm) on a McIlwain tissue chopper (The Mickle Laboratory Engineering, Guildford, UK). OHC were transferred to humidified 0.4 μm porous Millicell membranes (Millipore, Morsheim, France) and maintained in 1 mL serum-based medium (50% MEM-Hanks, 25% HBSS, 17 mM HEPES, 5 mM glucose, 1 mM L-glutamin, 25% horse serum, 0.5% gentamycin) at 37°C for 3 days. Thereafter, OHC were transferred to serum-free medium (50% MEM-Hanks, 25% HBSS, 17 mM HEPES, 5 mM glucose, 1 mM L-glutamin, 25% Neurobasal-A, 0.5% B27, 0.5% gentamycin) for 14 days at 37°C in 5% CO2. For pre-selection, propidium iodide (PI; 2 μM) was added to the OHC 12 hours prior to the experiments to exclude damaged OHC. For OGD, hippocampal slices were transferred to six-well-plates with 1 mL of 10 mM mannitol-containing glucose-free Ringer solution. Cultures were placed in a gas-tight chamber at 37°C. Oxygen was replaced by 95% N2 and 5% CO2 for 10 minutes and slices were incubated for another 40 minutes. Untreated controls were maintained for the same time under a normoxic atmosphere in glucose-containing Ringer solution. After OGD, OHC were returned to normoxic culture conditions. Cell death was quantified as described previously .
Co-cultivation of OHC with BM MNC and analysis of cellular damage
After OGD, slices were returned to normoxic standard culture conditions. For indirect co-cultivation 2.5x10E4 or 25x10E4 BM MNC were seeded under the interface cultures. After one and two days cell damage was determined by incubating OHC with PI (1 mg/mL) for two hours. Damage was analyzed in the cornu ammonis (CA1-CA2-CA3). To ensure comparability of data, fluorometric mean values obtained on day 1 were defined as 100%. All other data obtained are given as relative values.
Experimental stroke and cell transplantation
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the appropriate regional authorities (reference number TVV18/07). In total, 33 male spontaneously hypertensive rats (SHR) at the age of 18 month (weighing 392 ± 32 g) were subjected to permanent middle cerebral artery occlusion as described previously . The perioperative mortality amounted 36%. The remaining 21 SHR were randomly assigned to one of the following experimental groups: (1) transplantation of young BM MNCs, n = 7; (2) transplantation of old BM MNCs (n = 7); (3) injection of phosphate buffered solution (n = 7). Balanced randomization was performed by drawing lots. Exactly 24 h after stroke onset, 8x10E6 BM MNCs per kilogram bodyweight were transplanted intravenously via the tail vein. Accordingly, the control group received the same amount of vehicle solution at the same time. The application of cells or vehicle solution was performed by an investigator blinded to the group allocation.
Neurofunctional deficits were quantified by a blinded investigator using two independent functional tests. At first, the modified Neurological Severity Score (mNSS)  was ascertained on the day before stroke as well as on days 2, 4 and 7 and weekly thereafter until day 63. The ladder rung test  was carried out the day before stroke and on days 2, 14, 28, 42 and 56. Briefly, the animals crossed a horizontal ladder with randomly mounted rungs spacing between 1 and 5 cm. Each run was videorecorded using three technical replicates and subsequently analyzed for each step of each limb separately. In doing so, the total number of steps and the total number of paw placing errors was ascertained and averaged for an animal at one time point.
Magnetic resonance imaging
Lesion development was examined in vivo using magnetic resonance imaging (MRI; 1.5 T Gyroscan Intera human whole-body spectrometer equipped with a small loop RF-Coil (47 mm), Philips) on days 1, 8, 29 and 60. T2- weighted sequences (T2-TSE) were performed at each MRI session consisting of 20 transverse slices (matrix: 224 × 224; field of view: 50 mm; slice thickness: 1 mm). Corrected lesion volume was calculated by a blinded investigator as described previously  and expressed as the percentage of the day 1 infarct volume.
Data obtained from in vitro experiments, slices cultures and MR investigations was first analyzed for normal distribution using the Shapiro-Wilk test. According to the distribution of data, unpaired two-tailed t-test or Mann-Whitney U test was used to analyze statistical differences between two groups. More than two groups were analyzed by one-way ANOVA or one-way ANOVA on ranks followed by Holm-Sidak or Turkey´s post hoc test. Time series data obtained from behavioral tests were summarized as area under the curve (AUC)  integrating all times points later than day 2. The AUCs were analyzed by multivariate regression models treating the usage of young and old bone marrow and the performance on day 2 as independent variables. The latter variable is included in view of the large impact of the initial lesion with respect to the outcome. A p-value of 0.05 or less was considered statistically significant. All data are shown as mean ± SD.
Age-related changes in cell functionality
Neuroprotective effects of BM MNC in vitro are age-dependent
Aged hypertensive rats do not benefit from BM MNC transplantation
The question addressed by the present study was whether age influences the therapeutic concept of autologous BM MNC transplantation after acute stroke. The Framingham Study clearly demonstrated the relevance of age and high blood pressure for the lifetime risk of stroke  indicating the need to mimic these risk factors in preclinical stroke studies. Since BM MNCs offer the particular advantage of acute and autologous transplantability, age might influence both the patients’ susceptibility to and the functionality of the BM MNC graft.
By comparing the neuroprotective properties of human BM MNCs from young (24 ± 4 years) with aged (68 ± 1 years) donors in a cell culture model of cerebral hypoxia we found that young BM MNCs significantly suppress hippocampal cell death after oxygen glucose deprivation (OGD). This finding is in accordance with another recent in vitro study that revealed an attenuated amount of apoptotic neurons after hypoxic injury and cotreatment with BM MNC-derived supernatants . The authors discussed the release of trophic factors and the modulation of microglia as contributing factors to the observed neuroprotective effects.
In our hands, aged BM MNCs did not show neuroprotective capabilities in the hippocampal OGD model. A BM MNC subpopulation, the bone marrow derived mesenchymal stromal cells (BMSC) are supposed to account for antiapoptotic effects after ischemic damage [18, 19]. However, several studies revealed a decline in BMSC numbers and fitness with age. Thus it is tempting to speculate that senescent BM MNCs lack neuroprotective effects, as shown in the present study, due to an age-related drop in BMSC frequency and functionality .
In a second step, we evaluated the therapeutic efficacy of intravenously transplanted young and aged BM MNCs in aged hypertensive rats (SHR). Both BM MNCs from juvenile and elderly donors failed to decrease the lesion volume after experimental brain ischemia. Beyond that, functional recovery was not improved over a period of 56 days. These findings are, at least partly, in clear contrast to recent stroke studies demonstrating significant benefits of BM MNC transplantation in young and middle-aged (12 months old) healthy animals [5, 6, 8]. The differing results might be explainable by age and comorbid status of the laboratory animals used in this study. Aged individuals show a dysregulated cellular and genetic response to cerebral ischemia that finally determines a poor neurofunctional recovery. More precisely, augmented apoptosis and massive microglia activation that induces an enhanced inflammatory response account for accelerated infarct development in the aged brain [21, 22]. Likewise, stroke in senescent rats is associated with a greater degree of oxidative cellular injury . Another contributing factor might be the exacerbated astrocytic reaction in geriatric stroke rats that, in turn, impairs neurite outgrowth . One of the cellular mechanisms of neuronal plasticity after stroke is axonal sprouting. Interestingly, aging delays the expression of growth-promoting genes during the sprouting response while growth-inhibitory genes are induced at earlier stages than in its younger counterparts . Of note, enhancement of endogenous plasticity mechanisms such as axonal sprouting and synaptogenesis, amongst others, is considered to be a critical mode of action for cell-based therapies . Thus, the temporal mismatch of growth-associated gene expression in the aging brain may interfere with the plasticity-related effects of cell therapy. Most importantly, the age-related shift of pathophysiological sequences in stroke might require adjustments of the therapeutic setting such as a prolonged treatment period or higher dosages of BM MNCs.
Moreover, previous studies revealed that the final infarct volume in SH rats develops rapidly within 1 h after the onset of permanent ischemia . Thus, the lack of secondary infarct expansion in SH rats might additionally account for the absence of neuroprotective effects in this study. Unfortunately, our study is limited by the exclusive use of aged spontaneously hypertensive rats without controlling the age factor. Thus, the discrimination between the influence of hypertension, including its substantial impact on the cerebral microvessel system , and age is not possible. On the other hand, the combination of age, significant cardiovascular comorbidities, and a relatively advanced ischemic lesion development (sub-acute stage) describes the population of stroke patients which would primarily be eligible for BM MNC treatment in upcoming clinical trials.
Cell storage and processing may further influence the therapeutic potential of BM MNC. The cells used in our study had been cryopreserved prior to use, while the majority of positive therapeutic results were obtained in studies using freshly prepared BM MNC. Cryopreservation does not seem to affect the hematopoietic potential . However, it is unclear whether freezing and/or thawing alters potential neuroprotective capabilities, which probably depend on completely different physiological processes. In fact, it has been shown that cryopreservation affects BM MNC physiology. Even single freezing-thawing cycles can enhance intrinsic proteolytic activity leading to the cleavage of apoptosis-related proteins , even though the impact of this alteration (and potentially others) on neuroprotection is unknown. Thus, thorough research is needed to elucidate this impact.
Another limitation of our study is the transplantation of human BM MNCs to rodents without an immunosuppressive treatment. The absence of beneficial effects in aged SHRs might be simply a consequence of xenograft rejection. However, recent animal stroke studies described significantly improved recovery by BM MNCs, albeit the transplanted cells died immediately after injection [5, 31]. It is not conclusively elucidated so far, if and how long transplanted cells must survive to facilitate beneficial effects. In line with this, Thum and colleagues introduced the “dying stem cell hypothesis”. They suppose that apoptotic, rather than viable cells are responsible for the functional restoration after stem cell transplantation in ischemic injury via modulating the local immune response . A further decisive reason why we desisted from immunosuppression is that the commonly applied agents may distort the value of this study by their neuroprotective properties  and by impacting the immunological processes that ultimately determine progress and outcome after stroke .
Although not investigated in the present study, several further mechanisms by which BM MNCs might improve recovery after ischemic stroke are age-dependent. It has been shown that young BM MNCs promote neovascularization in models of limb ischemia  myocardial infarction  and ischemic white matter damage . However, aging impairs the angiogenic capacity of BM MNCs , a finding that is in agreement with an impaired VEGF production and migratory response to VEGF in aged BM MNCs . Furthermore, it has been shown that vasculogenesis after BM MNC transplantation is dependent on the CD34+ cell fraction  and that CD34+ cells enhance post-ischemic neurogenesis . Our finding that the frequency of hematopoietic progenitor cells is significantly reduced in senescent BM MNCs might therefore compromise the therapeutic efficacy of self-donated BM MNCs in aged patients.
In summary, a neuroprotective effect of young, but not of senescent BM MNCs in an in vitro model of cerebral ischemia was shown. Aged hypertensive rats, however, did not benefit from acute BM MNC treatment, regardless of the donor’s age. Age and comorbidity should thus be taken into consideration when studying the efficacy of autologous cell transplantation for stroke.
The authors wish to thank Prof. Dr. Klaus G. Reymann, Dr. Holger Braun and Cornelia Garz (Leibniz Institute for Neurobiology, Magdeburg, Germany) for valuable advice. Furthermore, we are grateful to Dr. Alexander Deten (Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany) for critically reviewing the manuscript. This work was made possible by a grant from the European Union (12853/2142; Development Bank of Saxony).
- Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001, 56: 1015–1020. 10.1212/WNL.56.8.1015PubMedView Article
- Chopp M, Li Y, Zhang ZG: Mechanisms underlying improved recovery of neurological function after stroke in the rodent after treatment with neurorestorative cell-based therapies. Stroke 2009, 40: S143-S145. 10.1161/STROKEAHA.108.533141PubMed CentralPubMedView Article
- Savitz SI, Misra V: Launching intravenous bone marrow cell trials for acute stroke. Regen Med 2009, 4: 639–641. 10.2217/rme.09.41PubMedView Article
- Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC: Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 2011, 70: 59–69. 10.1002/ana.22458PubMedView Article
- Brenneman M, Sharma S, Harting M, Strong R, Cox CS Jr, Aronowski J, Grotta JC, Savitz SI: Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab 2010, 30: 140–149. 10.1038/jcbfm.2009.198PubMed CentralPubMedView Article
- Giraldi-Guimaraes A, Rezende-Lima M, Bruno FP, Mendez-Otero R: Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res 2009, 1266: 108–120.View Article
- Yoshihara T, Ohta M, Itokazu Y, Matsumoto N, Dezawa M, Suzuki Y, Taguchi A, Watanabe Y, Adachi Y, Ikehara S, Sugimoto H, Ide C: Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. J Neurotrauma 2007, 24: 1026–1036. 10.1089/neu.2007.132RPubMedView Article
- Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD: A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004, 1007: 1–9. 10.1016/j.brainres.2003.09.084PubMedView Article
- Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA: The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006, 37: 345–350. 10.1161/01.STR.0000199613.38911.b2PubMedView Article
- Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991, 37: 173–182. 10.1016/0165-0270(91)90128-MPubMedView Article
- Sarnowska A, Braun H, Sauerzweig S, Reymann KG: The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. Exp Neurol 2009, 215: 317–327. 10.1016/j.expneurol.2008.10.023PubMedView Article
- Riegelsberger UM, Deten A, Posel C, Zille M, Kranz A, Boltze J, Wagner DC: Intravenous human umbilical cord blood transplantation for stroke: Impact on infarct volume and caspase-3-dependent cell death in spontaneously hypertensive rats. Exp Neurol 2011, 227: 218–223. 10.1016/j.expneurol.2010.11.008PubMedView Article
- Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M: Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32: 2682–2688. 10.1161/hs1101.098367PubMedView Article
- Metz GA, Whishaw IQ: Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination. J Neurosci Methods 2002, 115: 169–179. 10.1016/S0165-0270(02)00012-2PubMedView Article
- Kranz A, Wagner DC, Kamprad M, Scholz M, Schmidt UR, Nitzsche F, Aberman Z, Emmrich F, Riegelsberger UM, Boltze J: Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats. Brain Res 2010, 1315: 128–136.PubMedView Article
- Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990, 300: 230–235. 10.1136/bmj.300.6719.230PubMed CentralPubMedView Article
- Sharma S, Yang B, Strong R, Xi X, Brenneman M, Grotta JC, Aronowski J, Savitz SI: Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res 2010, 88: 2869–2876.PubMed CentralPubMed
- Chopp M, Li Y: Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002, 1: 92–100. 10.1016/S1474-4422(02)00040-6PubMedView Article
- Tate CC, Fonck C, McGrogan M, Case CC: Human mesenchymal stromal cells and their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia. Cell Transplant 2010, 19: 973–984. 10.3727/096368910X494885PubMedView Article
- Stolzing A, Jones E, McGonagle D, Scutt A: Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008, 129: 163–173. 10.1016/j.mad.2007.12.002PubMedView Article
- Popa-Wagner A, Badan I, Walker L, Groppa S, Patrana N, Kessler C: Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats. Acta Neuropathol 2007, 113: 277–293. 10.1007/s00401-006-0164-7PubMedView Article
- Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, Kessler C, Popa-Wagner A: Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab 2003, 23: 845–854.PubMedView Article
- Li S, Zheng J, Carmichael ST: Increased oxidative protein and DNA damage but decreased stress response in the aged brain following experimental stroke. Neurobiol Dis 2005, 18: 432–440. 10.1016/j.nbd.2004.12.014PubMedView Article
- Popa-Wagner A, Dinca I, Yalikun S, Walker L, Kroemer H, Kessler C: Accelerated delimitation of the infarct zone by capillary-derived nestin-positive cells in aged rats. Curr Neurovasc Res 2006, 3: 3–13. 10.2174/156720206775541732PubMedView Article
- Li S, Carmichael ST: Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol Dis 2006, 23: 362–373. 10.1016/j.nbd.2006.03.011PubMedView Article
- Bliss TM, Andres RH, Steinberg GK: Optimizing the success of cell transplantation therapy for stroke. Neurobiol Dis 2010, 37: 275–283. 10.1016/j.nbd.2009.10.003PubMed CentralPubMedView Article
- Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew AP, Barone FC: SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol 2008, 212: 53–62. 10.1016/j.expneurol.2008.03.011PubMedView Article
- Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010, 9: 689–701. 10.1016/S1474-4422(10)70104-6PubMedView Article
- Nicol A, Nieda M, Donaldson C, Denning-Kendall P, Truman C, Bradley B, Hows J: Cryopreserved human bone marrow stroma is fully functional in vitro. Br J Haematol 1996, 94: 258–265. 10.1046/j.1365-2141.1996.d01-1812.xPubMedView Article
- Schmidt-Mende J, Hellström-Lindberg E, Joseph B, Zhivotovsky B: Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells. J Immunol Methods 2000, 245: 91–94. 10.1016/S0022-1759(00)00285-4PubMedView Article
- Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, Grotta JC, Aronowski J, Savitz SI: Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res 2011, 89: 833–839. 10.1002/jnr.22614PubMed CentralPubMedView Article
- Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, Anker SD: The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005, 46: 1799–1802. 10.1016/j.jacc.2005.07.053PubMedView Article
- Sullivan PG, Sebastian AH, Hall ED: Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury. J Neurotrauma 2011, 28: 311–318. 10.1089/neu.2010.1646PubMed CentralPubMedView Article
- Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R: The immunology of acute stroke. Nat Rev Neurol 2012, 8: 401–410. 10.1038/nrneurol.2012.98PubMedView Article
- Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T: Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 2001, 103: 897–903. 10.1161/01.CIR.103.6.897PubMedView Article
- Zhang S, Guo J, Zhang P, Liu Y, Jia Z, Ma K, Li W, Li L, Zhou C: Long-term effects of bone marrow mononuclear cell transplantation on left ventricular function and remodeling in rats. Life Sci 2004, 74: 2853–2864. 10.1016/j.lfs.2003.10.035PubMedView Article
- Fujita Y, Ihara M, Ushiki T, Hirai H, Kizaka-Kondoh S, Hiraoka M, Ito H, Takahashi R: Early Protective Effect of Bone Marrow Mononuclear Cells Against Ischemic White Matter Damage Through Augmentation of Cerebral Blood Flow. Stroke 2010, 41: 2938–2943. 10.1161/STROKEAHA.110.596379PubMedView Article
- Zhuo Y, Li SH, Chen MS, Wu J, Kinkaid HY, Fazel S, Weisel RD, Li RK: Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010, 139: 1286–1294. 10.1016/j.jtcvs.2009.08.052PubMedView Article
- Sugihara S, Yamamoto Y, Matsuura T, Narazaki G, Yamasaki A, Igawa G, Matsubara K, Miake J, Igawa O, Shigemasa C, Hisatome I: Age-related BM-MNC dysfunction hampers neovascularization. Mech Ageing Dev 2007, 128: 511–516. 10.1016/j.mad.2007.06.009PubMedView Article
- Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T: Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006, 113: 1311–1325. 10.1161/CIRCULATIONAHA.105.541268PubMedView Article
- Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004, 114: 330–338.PubMed CentralPubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.